GLP‐1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea
Authors' conclusion
These data support the hypothesis that upregulation of VAT metabolic activity by GLP-1 contributes to its weight loss action in humans, and this subject warrants further detailed investigation.
Study context
- Population
- Individuals with obstructive sleep apnea and obesity
- Participants
- 30 individuals
- Comparison
- GLP-1 therapy-based weight loss regimen vs CPAP vs combination
- Primary endpoint
- VAT metabolic activity (VAT target to background ratio) on 18F-FDG positron emission tomography-computed tomography (PET-CT)
- Follow-up
- Baseline to 24 weeks
Methodological detailsproof-of-concept
- Proof-of-concept
Primary result
As reported in the abstract
VAT target to background ratio · 24 weeks
- GLP-1 treatment associated with a significant increase in visceral adipose tissue (VAT) target to background ratio
- CPAP not associated with a significant increase in VAT target to background ratio
Further findings
- Strong correlation between increase in VAT metabolic activity and degree of weight loss
Original publication
GLP‐1 therapy increases visceral adipose tissue metabolic activity: lessons from a randomized controlled trial in obstructive sleep apnea. Obesity (Silver Spring). Published 22 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →